Original language | English (US) |
---|---|
Pages (from-to) | 399-404 |
Number of pages | 6 |
Journal | American Journal of the Medical Sciences |
Volume | 357 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Externally published | Yes |
Keywords
- Comparative biology
- Lung fibrosis
- Recommendations
ASJC Scopus subject areas
- General Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of the Medical Sciences, Vol. 357, No. 5, 05.2019, p. 399-404.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Research in Pulmonary Fibrosis Across Species
T2 - Unleashing Discovery Through Comparative Biology
AU - for the Comparative Biology of Pulmonary Fibrosis Group
AU - Barnes, Teresa
AU - Brown, Kevin K.
AU - Corcoran, Brendan
AU - Glassberg, Marilyn K.
AU - Kervitsky, Dolly J.
AU - Limper, Andrew H.
AU - McGuire, Kay
AU - Williams, Kurt
AU - Roman, Jesse
N1 - Funding Information: Participants thank sponsors of the meeting from industry (Biogen Idec, Intermune, Boehringer Ingelheim Pharmaceuticals, Genentech), private foundations (Hermansky Puklak Syndrome Network, University of Louisville Foundation, University of Louisville Equine Center, Coalition of Pulmonary Fibrosis, Pulmonary Fibrosis Foundation, West Highland White Terrier Club of America, WHWTC of Southeast Texas, Skyehigh Westies, Shamrock Family Westies, Westie Foundation of America) and private donors (Wayne Kompare, Lindy Barrow, William Fisher, Roberta Macabee, Linda Wible and Anjelica Huston). Allison Pratt assisted with artistic design of logo, Susie Stone created a website and Glenn Vicary helped with data collection. Symposium sponsors had no input in the development of the symposium content, selection of speakers, or in the development of this manuscript. The symposium was sponsored by the Working Group on Lung Fibrosis of the Assembly of Respiratory Cell and Molecular Biology of the American Thoracic Society, and was supported by industry, The Westie Foundation, The Morris Animal Foundation, and The AKC Canine Health Foundation, among others. Symposium sponsors had no input in the development of the symposium content, selection of speakers or in the development of this manuscript. T.R.B. reports non-financial support from American Thoracic Society, personal fees from Coalition for Pulmonary Fibrosis, membership on board of directors for Westie Foundation of America and science board for New Amsterdam Sciences. K.K.B reports the following outside the submitted work, grants from NHLBI, personal fees from Biogen, Galecto, MedImmune, Roche/Genentech, ProMetic, Patara, Third Pole, Galapagos, Boehringer Ingelheim, Theravance, Three Lakes Partners and Veracyte. He has served on the Boards of the Pulmonary Fibrosis Foundation and the American Thoracic Society. B.C. reports grant support from the American Kennel Club and Westie Foundation of North America to support canine IPF research, and outside the submitted work from Zoetis Animal Health (USA), the Dogs Trust (UK) and the Roslin Institute (UK). M.K.G. has served as site PI or on the steering committee in industry-sponsored clinical trials (Actelion, Bellerophon, Boehringer Ingelheim, Celgene, Galapagos, Genentech/Roche, Gilead, InterMune, Stromedix and Toray) and has been funded by the National Institutes of Health, Genentech, and several private research foundations. She serves on the National Scientific Advisory Committee of the American Lung Association and has served as chair of the Women and Pulmonary group of the American College of Chest Physicians. D.J.K reports personal fees from Boehringer-Ingelheim, outside the submitted work; and was formerly Vice President of Patient Relations and Medical Affairs at the Pulmonary Fibrosis Foundation. A.H.L. has served as site PI or collaborator on industry-sponsored clinical trials (Roche-Genentech, Boehringer Ingelheim) and has been funded by the National Institutes of Health and The Hurvis and Brewer Foundations. He has served on the Boards of the Pulmonary Fibrosis Foundation. K.W. has received research funding through the AKC Canine Health Foundation for a separate project. J.R. has served as site PI or collaborator in industry-sponsored clinical trials (Gilead, InterMune, ImmuneWorks, Boehringer Ingelheim, Bristol Myers Squibb) and is funded by the National Institutes of Health and the Department of Veterans Affairs. He served on the Boards of the Pulmonary Fibrosis Foundation and the American Lung Association-Midland States. Funding Information: The symposium was sponsored by the Working Group on Lung Fibrosis of the Assembly of Respiratory Cell and Molecular Biology of the American Thoracic Society, and was supported by industry, The Westie Foundation, The Morris Animal Foundation, and The AKC Canine Health Foundation, among others. Symposium sponsors had no input in the development of the symposium content, selection of speakers or in the development of this manuscript. T.R.B. reports non-financial support from American Thoracic Society, personal fees from Coalition for Pulmonary Fibrosis, membership on board of directors for Westie Foundation of America and science board for New Amsterdam Sciences. K.K.B reports the following outside the submitted work, grants from NHLBI, personal fees from Biogen, Galecto, MedImmune, Roche/Genentech, ProMetic, Patara, Third Pole, Galapagos, Boehringer Ingelheim, Theravance, Three Lakes Partners and Veracyte. He has served on the Boards of the Pulmonary Fibrosis Foundation and the American Thoracic Society. B.C. reports grant support from the American Kennel Club and Westie Foundation of North America to support canine IPF research, and outside the submitted work from Zoetis Animal Health (USA), the Dogs Trust (UK) and the Roslin Institute (UK). M.K.G. has served as site PI or on the steering committee in industry-sponsored clinical trials (Actelion, Bellerophon, Boehringer Ingelheim, Celgene, Galapagos, Genentech/Roche, Gilead, InterMune, Stromedix and Toray) and has been funded by the National Institutes of Health, Genentech, and several private research foundations. She serves on the National Scientific Advisory Committee of the American Lung Association and has served as chair of the Women and Pulmonary group of the American College of Chest Physicians. D.J.K reports personal fees from Boehringer-Ingelheim, outside the submitted work; and was formerly Vice President of Patient Relations and Medical Affairs at the Pulmonary Fibrosis Foundation. A.H.L. has served as site PI or collaborator on industry-sponsored clinical trials (Roche-Genentech, Boehringer Ingelheim) and has been funded by the National Institutes of Health and The Hurvis and Brewer Foundations. He has served on the Boards of the Pulmonary Fibrosis Foundation. K.W. has received research funding through the AKC Canine Health Foundation for a separate project. J.R. has served as site PI or collaborator in industry-sponsored clinical trials (Gilead, InterMune, ImmuneWorks, Boehringer Ingelheim, Bristol Myers Squibb) and is funded by the National Institutes of Health and the Department of Veterans Affairs. He served on the Boards of the Pulmonary Fibrosis Foundation and the American Lung Association-Midland States.
PY - 2019/5
Y1 - 2019/5
KW - Comparative biology
KW - Lung fibrosis
KW - Recommendations
UR - http://www.scopus.com/inward/record.url?scp=85063000095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063000095&partnerID=8YFLogxK
U2 - 10.1016/j.amjms.2019.02.005
DO - 10.1016/j.amjms.2019.02.005
M3 - Article
C2 - 30879739
AN - SCOPUS:85063000095
SN - 0002-9629
VL - 357
SP - 399
EP - 404
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 5
ER -